Cheryl Crozier
Overview
Explore the profile of Cheryl Crozier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lautert-Dutra W, M Melo C, Chaves L, Crozier C, P Saggioro F, Reis R, et al.
Mol Cytogenet
. 2024 May;
17(1):11.
PMID: 38704603
Background: In prostate cancer (PCa), well-established biomarkers such as MSI status, TMB high, and PDL1 expression serve as reliable indicators for favorable responses to immunotherapy. Recent studies have suggested a...
2.
Lautert-Dutra W, Melo C, Chaves L, Sousa F, Crozier C, Dion D, et al.
Cancers (Basel)
. 2024 Apr;
16(8).
PMID: 38672562
Prostate cancer (PCa) is an immunologically cold tumor and the molecular processes that underlie this behavior are poorly understood. In this study, we investigated a primary cohort of intermediate-risk PCa...
3.
Lautert-Dutra W, M Melo C, Chaves L, Souza F, Crozier C, Sundby A, et al.
Front Oncol
. 2023 Nov;
13:1280943.
PMID: 37965470
The diverse clinical outcomes of prostate cancer have led to the development of gene signature assays predicting disease progression. Improved prostate cancer progression biomarkers are needed as current RNA biomarker...
4.
Bayani J, Kornaga E, Crozier C, Jang G, Bathurst L, Kalatskaya I, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-13.
PMID: 35100692
Purpose: Hormone receptor-positive breast cancer remains an ongoing therapeutic challenge, despite optimal anti-endocrine therapies. In this study, we assessed the prognostic ability of genomic signatures to identify patients at risk...
5.
Bayani J, Poncet C, Crozier C, Neven A, Piper T, Cunningham C, et al.
NPJ Breast Cancer
. 2021 Jul;
7(1):98.
PMID: 34312396
Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated...
6.
Bartlett J, Bayani J, Kornaga E, Danaher P, Crozier C, Piper T, et al.
PLoS One
. 2020 Sep;
15(9):e0238593.
PMID: 32881987
Multiparametric assays for risk stratification are widely used in the management of breast cancer, with applications being developed for a number of other cancer settings. Recent data from multiple sources...
7.
Sabine V, Crozier C, Brookes C, Drake C, Piper T, van de Velde C, et al.
J Clin Oncol
. 2014 Jul;
32(27):2951-8.
PMID: 25071141
Purpose: Deregulation of key PI3K/AKT pathway genes may contribute to endocrine resistance in breast cancer (BC). PIK3CA is the most frequently mutated gene in luminal BC (35%); however, the effect...
8.
Crozier C, Erickson-Wittmann B, Movsas B, Owen J, Khalid N, Wilson J
J Healthc Qual
. 2013 Jul;
33(5):49-57.
PMID: 23845133
To demonstrate how the American College of Radiology, Quality Research in Radiation Oncology (QRRO) process survey database can serve as an evidence base for assessing quality of care in radiation...
9.
Zelefsky M, Lee W, Zietman A, Khalid N, Crozier C, Owen J, et al.
Pract Radiat Oncol
. 2013 Mar;
3(1):2-8.
PMID: 23471563
Purpose: To test the feasibility of using proposed quality indicators to assess radiotherapy quality in prostate cancer management based on a 2007 stratified random survey of treating academic and non-academic...
10.
Goodman K, Khalid N, Kachnic L, Minsky B, Crozier C, Owen J, et al.
Int J Radiat Oncol Biol Phys
. 2012 Oct;
85(2):355-62.
PMID: 23040221
Background: The specific aim was to determine national patterns of radiation therapy (RT) practice in patients treated for stage IB-IV (nonmetastatic) gastric cancer (GC). Methods And Materials: A national process...